Drugs Controller General of India
The Drugs Controller General of India (DCGI) has said that the blood center across the nation can charge only processing costs as blood is not for sale. The DCGI has banned all charges except supply and processing costs on blood units.
In reference with the 62nd meeting of the Drugs Consultative Committee held on September 26, 2023, the DCGI has highlighted to address the issue of overcharging for blood, that blood is not meant for sale but for supply, and consequently, only processing costs should be levied by blood centres.
In an official communication to all states and UTs Drug Controllers Cum Licensing Authority on December 26, the DCGI stated, “It was recommended with respect to agenda No. 18 of ATR point 3, for overcharging of blood, it was opined that blood is not for sale, it is only for supply and only processing cost may be charged by the blood centre”=.
The blood centres have been now authorised to charge only processing fees for blood or blood components. These fees have been stipulated to range between Rs 250 to Rs 1,550 for blood or blood components. The DCGI has urged states and Union Territory drug controllers to ensure strict adherence to these guidelines by all blood centres within their jurisdiction.
Union Health Minister JP Nadda was admitted to AIIMS Delhi following the complaint of breathing…
India has achieved a milestone in organ transplantation, recording its highest-ever number of transplants in…
Mothers Against Vaping (MAV), a collective of mothers worried about the future of their children,…
A parliamentary committee has recommended mandatory kidney function tests every six months for everyone aged…
A parliamentary committee has recommended that a private hospital room in a metropolitan city should…
The Integrated Health & Wellbeing (IHW) Council marked World IVF Day by convening the 7th…